Side-by-side comparison of AI visibility scores, market position, and capabilities
AI molecular discovery unicorn ($1.3B valuation). 100x improvement in de novo antibody design success. Backed by OpenAI. Eli Lilly partnership. Founded 2023, SF. $225M+ raised.
Chai Discovery is an AI-driven molecular discovery company founded in 2024 and headquartered in San Francisco. The company was spun out of research conducted by scientists with backgrounds at leading computational biology and AI organizations, with the founding mission of applying the latest advances in generative AI to accelerate drug discovery — particularly the historically difficult challenge of designing novel antibodies and small molecules from scratch rather than optimizing known chemical scaffolds.\n\nChai's core technology is a foundation model for molecular structure prediction and de novo design that operates across proteins, small molecules, nucleic acids, and their complexes. The company's flagship research achievement is a reported 100-fold improvement in de novo antibody design success rates, enabling the generation of functional antibody candidates without requiring extensive experimental screening campaigns. Chai Discovery has established a research partnership with Eli Lilly, one of the world's largest pharmaceutical companies, to apply its platform to therapeutic target programs. The company is backed by OpenAI, reflecting the deep connection between large-scale AI modeling techniques and the biological sequence-structure-function prediction task.\n\nChai Discovery reached a $1.3 billion valuation within its first year of operation, an exceptionally rapid ascent reflecting the strategic premium investors place on AI-native molecular discovery platforms. The company operates at the intersection of structural biology, generative AI, and therapeutic development, competing with platforms like Isomorphic Labs, Recursion, and Insilico Medicine in the race to demonstrate AI-designed drugs in human clinical trials.
West Pharmaceutical Services (WST) reported ~$3.0B revenue in FY2024. Designs packaging components and delivery systems for injectable drugs — critical for vaccine and biologic drug manufacturing. HQ: Exton, PA.
West Pharmaceutical Services, Inc. is the global leader in packaging components and delivery systems for injectable medications, designing and manufacturing the stoppers, closures, caps, and drug delivery systems that seal vials, syringes, and cartridges containing vaccines, biologics, and injectable drugs. Every major pharmaceutical company and biologic manufacturer relies on West's containment solutions — the small rubber stopper sealing an mRNA vaccine vial or insulin cartridge is almost certainly a West product.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.